GlassScriptPhysician profile
Frederic M Civish
NPI 1124137278
$4,042.59
in general payments reported to CMS, 2019-2025
34 companies · $776 in 2025
The $776 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $266 · 2021: $413 · 2022: $563 · 2023: $746 · 2024: $798 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,319.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $888.80 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $306.63 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.66 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novo Nordisk INC | $294.32 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $263.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $219.16 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $193.26 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $175.28 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Amgen INC. | $174.47 | 2019-2024 | Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.14 | 2025 | Caplyta |
| Astellas Pharma US INC | $123.86 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $108.37 | 2023-2025 | |
| Inspire Medical Systems, INC. | $93.11 | 2024-2025 | Inspire |
| Janssen Pharmaceuticals, INC | $83.95 | 2019-2021 | |
| Glaxosmithkline, LLC. | $78.41 | 2019-2023 | Shingrix, Arexvy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $74.71 | 2019-2022 | |
| Alkermes, INC. | $70.38 | 2024-2025 | Lybalvi |
| Boston Scientific Corporation | $58.88 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $55.35 | 2019 | |
| Axsome Therapeutics, INC. | $45.07 | 2024-2025 | Auvelity |
| Indivior INC. | $43.31 | 2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $25.28 | 2024 | Rexulti |
| Renalytix Ai, INC. | $20.73 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.77 | 2019 | |
| Rgh Enterprises LLC | $19.07 | 2025 | |
| Idorsia Pharmaceuticals US INC | $18.06 | 2023 | Quviviq |
| Cranial Technologies, INC | $17.70 | 2020 | |
| Dexcom, INC. | $16.83 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $15.85 | 2021 | |
| Viatris Specialty LLC | $15.58 | 2025 | Yupelri |
| Gilead Sciences, INC. | $15.18 | 2020 | |
| Genentech USA, INC. | $14.08 | 2019 | |
| Medtronic Minimed, INC. | $13.77 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederic Civish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.